ArticleScientific reports2025
Association between adiponectin single nucleotide polymorphisms and the risk of diabetic polyneuropathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Key hub genes and pathways associated with HCV-related hepatocellular carcinoma as potential diagnostic biomarkers.Journal, genetic engineering & biotechnology · 2026Article
- Genetic polymorphisms in DNA repair gene XRCC1 and the risk of diabetic polyneuropathy.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic factors play a significant role in the occurrence and clinical course of diabetic peripheral neuropathy (DPN). This research aimed to search the influence of adiponectin single nucleotide polymorphisms (SNPs) on the risk of developing and the severity of DPN in Egyptian patients. Adiponectin SNPs were genotype in 360 participants comprising diabetic sufferers with and without peripheral neuropathy and healthy volunteers via the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach. Regarding the + 45 T/G SNP, the TG/ and GG genotypes and the G allele were linked to an rised risk of DPN by comparing the DPN group with both the control and diabetic patients without peripheral neuropathy (DWPN) groups, and when comparing the DWPN group with the control group. Concerning + 276 G/T SNP, the GT genotype and T allele were linked to a declined risk of occuring DPN when comparing the DPN group with both other groups. Patients with DPN had greater frequencies of the GA genotype of the - 11,391 G/A SNP than individuals in the control group, while patients with DPN had greater frequencies of the AA genotype than patients in the DWPN group. Regarding clinic-pathological features, a meaningful rise in the mean values of fasting blood glucose (FBG), duration of the disease, and Toronto Clinical Neuropathy Severity Score (TCSS) were noted in the + 45 GG genotype and G allele carriers. Contrariwise, the + 276 TT genotype carriers had lower mean values for the same clinic-pathological features. For the T allele carriers, the same results were observed in case of duration of the disease and TCSS value. Our results concluded that adiponectin + 45 T/G SNP could be a risk factor considering DPN and the severity of the disease. The - 11391G/A SNP might be associated with DPN. In addition, + 276 G/T SNP could be a protective factor regarding DPN and the severity of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.